OrbiMed Advisors MLTX Position
Exited8-Fund ConvergenceOrbiMed Advisors exited their position in MoonLake Immunotherapeutics (MLTX) in Q4 2023, after holding the stock for 3 quarters.
The position was first reported in Q2 2023 and has been tracked across 3 quarterly 13F filings.
MLTX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Sonelokimab in 274 days (Jan 15, 2027), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 20.0% of float with 5.8 days to cover, indicating significant bearish positioning against the stock.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Full company profile →Short Interest
20.0%
5.8 days to cover
OrbiMed Advisors MLTX Position History
Frequently Asked Questions
Does OrbiMed Advisors own MLTX?
No. OrbiMed Advisors exited their position in MoonLake Immunotherapeutics (MLTX) in Q4 2023. They previously held the stock for 3 quarters.
How many hedge funds own MLTX?
8 specialist biotech hedge funds currently hold MLTX, including BVF Partners, Cormorant Asset Management, Avoro Capital Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy MLTX?
OrbiMed Advisors's position in MLTX was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's MLTX position increasing or decreasing?
OrbiMed Advisors completely exited their MLTX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MLTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →